Every 8-K that Nutex Health Inc (NUTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NUTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUTX filings page.
Nutex Health Inc. (NUTX) reports further details on a previously disclosed cybersecurity incident involving unauthorized activity on its computer network. An investigation, supported by an independent cybersecurity response team and forensic experts, indicates that an unauthorized third party accessed and exfiltrated data from Nutex servers, including patient and employee, credentialed provider, business and financial information that is private and/or confidential. The third party has threatened to post this information externally.
To date, Nutex states it has not identified any material impact on business operations or financial reporting systems. The company is continuing to assess the scope of data involved, potential impacts, and required regulatory and legal notifications, including notifications to impacted patients. A purported class action, Haley v. Nutex Health, Inc., has been filed in federal court in Texas in connection with the incident, and Nutex states it is currently unable to predict the outcome or the overall impact of the incident or related litigation on its business, financial condition, results of operations, or stock price.
Nutex Health Inc. (NUTX) reported that it recently detected unauthorized activity involving data stored on its computer network. The company engaged an independent third-party cybersecurity response team and forensic experts, activated a cybersecurity response plan, implemented containment measures, and notified law enforcement.
Preliminary findings indicate that certain information on Nutex Health’s servers was accessed and exfiltrated by an unauthorized third party, including some potentially private or confidential data. As of August 24, 2026, Nutex Health states it has not identified any material impact on business operations or financial reporting systems and does not believe the incident has had, or is reasonably likely to have, a material impact on its business strategy, operations, financial condition, or results of operations. The company is continuing its investigation, assessing whether patient, employee, provider, confidential business, financial information, or intellectual property was involved, and is evaluating regulatory and legal notification obligations, including notifications to impacted patients if required.
Nutex Health Inc. reports that on August 11, 2026, the U.S. Court of Appeals for the Fifth Circuit, sitting en banc, issued a decision in Texas Medical Association v. HHS affecting how insurers calculate the Qualifying Payment Amount (QPA) under the No Surprises Act. The court held that insurers may not include so‑called “ghost rates” in QPA calculations and must include bonus and incentive payments, vacating key portions of a July 2021 interim final rule issued by federal Departments. Nutex, as a healthcare provider subject to No Surprises Act reimbursement and arbitration processes linked to the QPA, highlights that the court described prior inclusion of ghost rates as artificially suppressing QPAs and noted that arbitration awards exceeded the QPA in 85% of disputes. The decision directs federal Departments to create new rules consistent with the statute while allowing existing QPAs to be used in the interim through enforcement discretion.
Nutex Health Inc. reported strong results for the three and six months ended June 30, 2026. For the quarter, net income attributable to Nutex Health rose to $65.8 million, or diluted EPS of $9.38, compared with a loss of $17.7 million, or $(2.95) per share, a year earlier. Quarterly EBITDA was $94.1 million and Adjusted EBITDA $90.0 million. For the first half of 2026, net income attributable to Nutex Health was $112.6 million with diluted EPS of $15.87, and Adjusted EBITDA was $147.5 million. Total revenue was $210,752 (in thousands) for the quarter and $427,237 (in thousands) for the first half, compared with $243,985 and $455,774 (in thousands) in 2025.
Hospital Division volumes increased, with 49,962 total visits in Q2 2026, up 9.6% year over year, and 99,704 visits for the first half, up 6.2%. Net cash provided by operating activities was $34.2 million in Q2 and $109.7 million for the first half, up from $27.3 million and $78.2 million in the prior-year periods. As of June 30, 2026, cash and cash equivalents were $205,208 (in thousands), long-term debt, net, was $31.1 million, and total equity was $507,312 (in thousands).
Nutex Health Inc. entered into a First Amendment to its Payment Dispute Resolution Services Agreement with HaloMD, L.L.C., effective June 30, 2026. The amendment shifts fees to a pay-on-collected basis retroactive to the original May 1, 2024 agreement, adjusts the service fee structure for federal and state net settlement amounts obtained on or after July 1, 2026, and allows HaloMD access to remittance data to confirm payment of awarded claims.
The company also gains the right to handle dispute resolution services in-house or through another vendor for certain future hospital facilities, and the agreement’s initial term is extended through December 31, 2029, with automatic one-year renewals. Separately, CMS and other federal agencies cut the Federal IDR non-refundable administrative fee from $115 to $15 per party per dispute, effective June 11, 2026. Nutex Health expects these changes to reduce overall arbitration-related costs.
Nutex Health Inc. reported higher profitability for the three months ended March 31, 2026. Total revenue rose 2.2% to $216.5 million, led by hospital division revenue of $207.6 million and modest growth in population health management. Hospital division visits increased 3.1% year over year to 49,742.
Net income attributable to Nutex Health climbed to $46.8 million, with diluted EPS of $6.52, up from $3.33 a year earlier. EBITDA was $68.3 million, while Adjusted EBITDA declined to $57.6 million from $72.8 million. Operating cash flow improved to $75.5 million, cash and cash equivalents reached $207.3 million, and long-term debt, net decreased to $24.3 million.
Nutex Health Inc. held its annual stockholder meeting on April 23, 2026. There were 5,628,591 common shares eligible to vote, and 3,900,175 shares were voted, representing about 69.29% of eligible shares.
All seven director nominees were elected to serve until the 2027 annual meeting. Stockholders also approved, on an advisory basis, the compensation of the named executive officers. In addition, stockholders ratified Grant Thornton LLP as Nutex Health’s independent registered public accounting firm for the year ending December 31, 2026.
Nutex Health reported strong growth for 2025 while highlighting its reliance on arbitration-related revenue and a weaker fourth quarter. For the year ended December 31, 2025, total revenue rose to $875.3 million from $479.9 million, driven mainly by the hospital division, which generated $844.2 million. About $527.8 million of hospital revenue, roughly 63%, came from higher acuity claims and success in the Independent Dispute Resolution process, where the company reports prevailing in over 85% of determinations with an average collection rate above 85%.
Full-year net income attributable to Nutex Health increased to $70.8 million, including $117.0 million of non‑cash stock‑based compensation tied to earn‑out shares. Diluted EPS was $10.48. EBITDA attributable to Nutex Health was $168.6 million, and Adjusted EBITDA rose to $259.6 million. Net cash from operating activities totaled $248.1 million. As of year‑end, the company reported total assets of $918.5 million, including cash and cash equivalents of $185.6 million and long‑term debt, net, of $29.2 million.
Fourth quarter 2025 revenue fell to $151.7 million from $257.6 million a year earlier, largely due to a one‑time $55.0 million cumulative true‑up for ineligible arbitration claims and the absence of $69.0 million of arbitration revenue that benefited the prior‑year quarter. Adjusted EBITDA for the quarter declined to $16.6 million. After normalizing for these items, the company states that fourth quarter 2025 revenue would have exceeded the prior‑year period. Hospital division visits grew 11.8% for the full year to 188,279, with a 6.1% increase in the fourth quarter. Nutex also indicated it is launching a second stock repurchase program.
Nutex Health Inc. (NUTX) filed a current report to note that its independent auditor, Marcum LLP, has provided formal consent for its audit report to be used in existing registration statements. The consent, filed as Exhibit 23.1, covers Marcum’s report on Nutex Health’s consolidated balance sheet as of December 31, 2023, along with the related consolidated statements of operations, changes in equity and cash flows for the two-year period ended December 31, 2023. That audit report is included in Nutex Health’s Form 10-K/A filed on November 18, 2025. This is a routine step that allows Nutex to continue using its audited financial statements in connection with previously filed registration statements.
Nutex Health Inc. (NUTX) reported that it has released its financial and operating results for the third quarter ended September 30, 2025. The company announced these results on November 19, 2025 and made them available through a press release.
The press release is furnished as Exhibit 99.1 to this current report on Form 8-K, and is designated as furnished rather than filed under securities laws, meaning it is not automatically incorporated into other securities offerings or filings unless expressly stated.
Nutex Health Inc. reported that it has announced its financial and operating results for the second quarter ended June 30, 2025. The company is sharing these results through a press release dated November 18, 2025, which is furnished as Exhibit 99.1. The company states that this results information, including the exhibit, is being furnished rather than filed under securities laws and will only be incorporated into other documents if expressly stated there.
Nutex Health Inc. reported that it has released its financial and operating results for the first quarter ended March 31, 2025. The company announced these results on November 18, 2025 and made them available through a press release furnished as an exhibit to this report. The press release, dated November 14, 2025, is provided as Exhibit 99.1 and contains the detailed figures and operational updates for the quarter.
The company also clarified that the information in this results announcement, including the press release, is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
Nutex Health Inc. filed a current report to announce that it has released its financial and operating results for the fourth quarter and full year ended December 31, 2024. The results are provided in a press release dated November 18, 2025, which is furnished as Exhibit 99.1 to this report. The company also clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.
Nutex Health Inc. filed an 8‑K announcing it issued a press release with anticipated preliminary financial metrics for the period ended September 30, 2025, furnished as Exhibit 99.1.
The company also updated its Nasdaq listing status. Nutex is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to not timely filing its Quarterly Report on Form 10‑Q for the period ended June 30, 2025. The company submitted a compliance plan on October 15, 2025, and Nasdaq granted an extension on October 16, 2025 to file the June 30, 2025 Form 10‑Q by December 12, 2025. If Nutex does not file by December 12, 2025, Nasdaq staff will issue a delisting notice, which the company may appeal to a Nasdaq Hearings Panel.
Nutex Health, Inc. appointed Michael Bamburg as Chief Operating Officer and disclosed the principal terms of his employment agreement dated September 16, 2025. Bamburg, age 43, joins from HCA Houston Healthcare with a background in payor contracting and provider operations and holds a B.S. in Healthcare Administration and an MBA. The two-year agreement provides a base salary of $415,000 with automatic two-year extensions unless timely notice is given, eligibility for an annual cash bonus up to 60% of base salary, participation in long-term incentive awards valued up to 60% of base salary if granted, and a $100,000 signing bonus payable over four quarters if he remains employed at least 12 months. The agreement includes twelve months' severance and health subsidy if terminated without cause or for good reason, and standard accrual and reimbursement provisions. The filing incorporates the full agreement as Exhibit 10.1.
Nutex Health, Inc. appointed Michael L. Reed as Lead Independent Director effective September 2, 2025. Mr. Reed has been a director since April 2022 and serves on the Audit, Compensation, and Nominating and Corporate Governance Committees. In the new role he will preside over executive sessions of independent directors, facilitate communication between independent directors and the Chairman/CEO, and act as a liaison between the Board and management, consistent with the company’s governance guidelines and Nasdaq Listing Rule 5605. The appointment carries additional compensation under the company’s existing director compensation program disclosed in the proxy filed June 2, 2025.
Nutex Health Inc. reports that a putative securities class action was filed on August 22, 2025 in the U.S. District Court for the Southern District of Texas, captioned Anjana Bhagavan v. Nutex Health Inc. (Case No. 4:25-cv-03999).
The complaint names the company, its Chairman and Chief Executive Officer, its Chief Financial Officer, and its President and Director as defendants and asserts claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The allegations track a recent short seller report, and the plaintiff seeks unspecified damages.
Nutex Health disputes the allegations and intends to vigorously defend the lawsuit. The company states it cannot predict the outcome or estimate the financial impact, but acknowledges that an adverse ruling could have a material adverse effect on its financial position or results of operations.
Nutex Health Inc. filed a current report announcing that on August 14, 2025 it issued a press release with certain anticipated financial results and related information. The company furnished this press release as Exhibit 99.1, specifying that the information in Item 2.02 and the exhibit is being provided for informational purposes and is not deemed filed under the Exchange Act, nor automatically incorporated into other securities filings unless specifically referenced.